Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Dalpiciclib

From Wikipedia, the free encyclopedia
Chemical compound

Pharmaceutical compound
Dalpiciclib
Clinical data
Other namesSHR6390
Identifiers
  • 6-Acetyl-8-cyclopentyl-5-methyl-2-[(5-piperidin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC25H30N6O2
Molar mass446.555 g·mol−1
3D model (JSmol)
  • CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)C4CCNCC4)C5CCCC5)C(=O)C
  • InChI=1S/C25H30N6O2/c1-15-20-14-28-25(29-21-8-7-18(13-27-21)17-9-11-26-12-10-17)30-23(20)31(19-5-3-4-6-19)24(33)22(15)16(2)32/h7-8,13-14,17,19,26H,3-6,9-12H2,1-2H3,(H,27,28,29,30)
  • Key:SGJLSPUSUBJWHO-UHFFFAOYSA-N

Dalpiciclib is a drug for the treatment of various forms of cancer.[1]

In China, dalpiciclib is approved for use in combination withfulvestrant for treatment ofHR-positive,HER2-negative recurrent, ormetastatic breast cancer in patients who have progressed after previous endocrine therapy.[2]

Dalpicicilib is aCDK inhibitor that targets the CDK4 and CDK6 isoforms.[3]

References

[edit]
  1. ^Chen X, Shen K (June 2023). "Dalpiciclib in advanced breast cancer".The Lancet. Oncology.24 (6):578–579.doi:10.1016/S1470-2045(23)00228-0.PMID 37269836.
  2. ^"Dalpiciclib in Combination with Letrozole or Anastrozole Significantly Improved Progression-free Survival in Systemic Treatment-naive, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer".hengrui.com.
  3. ^Sheikh MS, Satti SA (2021)."The emerging CDK4/6 inhibitor for breast cancer treatment".Molecular and Cellular Pharmacology.13 (3):9–12.PMC 8896653.PMID 35251463.


Stub icon

Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Dalpiciclib&oldid=1268128888"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp